Search by Drug Name or NDC
NDC 00025-1021-31 ALDACTAZIDE 50; 50 mg/1; mg/1 Details
ALDACTAZIDE 50; 50 mg/1; mg/1
ALDACTAZIDE is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is HYDROCHLOROTHIAZIDE; SPIRONOLACTONE.
MedlinePlus Drug Summary
The combination of spironolactone and hydrochlorothiazide is used to treat high blood pressure. This medication is also used to treat patients with edema (fluid retention) caused by various conditions, including heart, liver, or kidney disease. Spironolactone is in a class of medications called aldosterone receptor antagonists. It causes the kidneys to eliminate unneeded water and sodium from the body into the urine, but reduces the loss of potassium from the body. Hydrochlorothiazide is in a class of medications called diuretics (''water pills''). It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 00025-1021-31Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Spironolactone and Hydrochlorothiazide
Product Information
| NDC | 00025-1021 |
|---|---|
| Product ID | 0025-1021_675ddb03-da87-4741-ad30-31653d578e39 |
| Associated GPIs | 37990002200320 |
| GCN Sequence Number | 006814 |
| GCN Sequence Number Description | spironolact/hydrochlorothiazid TABLET 50 MG-50MG ORAL |
| HIC3 | R1L |
| HIC3 Description | POTASSIUM SPARING DIURETICS IN COMBINATION |
| GCN | 82331 |
| HICL Sequence Number | 002900 |
| HICL Sequence Number Description | SPIRONOLACTONE/HYDROCHLOROTHIAZIDE |
| Brand/Generic | Brand |
| Proprietary Name | ALDACTAZIDE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | spironolactone and hydrochlorothiazide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 50; 50 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | HYDROCHLOROTHIAZIDE; SPIRONOLACTONE |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | Aldosterone Antagonist [EPC], Aldosterone Antagonists [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA012616 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00025-1021-31 (00025102131)
| NDC Package Code | 0025-1021-31 |
|---|---|
| Billing NDC | 00025102131 |
| Package | 100 TABLET, FILM COATED in 1 BOTTLE (0025-1021-31) |
| Marketing Start Date | 1978-01-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |